TrialThe oncologist2011

Patient-reported outcomes in a phase iii study of everolimus versus placebo in patients with metastatic carcinoma of the kidney that has progressed on vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy.

Jennifer L Beaumont et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.